When used to prevent breast cancer recurrence, tamoxifen doubles the risk of non-alcoholic steatohepatitis in overweight women, according to the results of a recent randomized, double-blind trial; but three's no evidence to suggest progression to cirrhosis after following patients for about 9 years.
When used to prevent breast cancer recurrence, tamoxifen doubles the risk of non-alcoholic steatohepatitis in overweight women, according to the results of a recent randomized, double-blind trial; but three's no evidence to suggest progression to cirrhosis after following patients for about 9 years.
To reach that conclusion, Italian researchers randomly assigned about 5,400 healthy women who had had hysterectomies to receive either 20 mg tamoxifen or placebo daily for five years. During follow-up, 64 women saw their alanine aminotransferase levels climb at least twice in 6 months. Of these, 12 tested positive for hepatitis C virus and 52 (34 tamoxifen, 18 placebo) were confirmed by ultrasonography to have non-alcoholic fatty liver disease (hazard ratio 2.0).
Those women who were overweight, obese, had hypercholesterolemia, or arterial hypertension were 2.4, 3.6, 3.4, and 2.0 times as likely, respectively, to develop non-alcoholic fatty liver disease as those with none of these conditions.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More